Tyvaso (treprostinil) Drug Overview & Product Profile 2019 - ResearchAndMarkets.com - Yahoo Finance

Posted: 16 Jul 2019 07:58 AM PDT

DUBLIN--(BUSINESS WIRE)--

The "Tyvaso" report has been added to ResearchAndMarkets.com's offering.

United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil, Tyvaso is better tolerated than continuously and subcutaneously administered Remodulin.

Analyst Outlook

United Therapeutics has created a large market niche for its inhaled treprostinil formulation, Tyvaso, despite the drug being relegated to later lines of therapy and being unavailable outside the US. However, this niche is now under threat from newer, more convenient oral prostacyclins such as Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku), which further possesses a much stronger clinical dataset, as well as United Therapeutics' own oral Orenitram (treprostinil).

While these products have carved out a portion of Tyvaso's market share, United Therapeutics may yet recoup losses through a first-to-market label expansion in pulmonary hypertension associated with lung disease (PH-LD). This will revive Tyvaso's sales growth and dampen potential competition from LIQ861 (treprostinil; Liquidia Technologies) - a dry powder for inhalation currently in Phase III.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Tyvaso: Pulmonary hypertension

LIST OF FIGURES

Figure 1: Tyvaso for pulmonary hypertension - SWOT analysis

Figure 2: The authors drug assessment summary of Tyvaso for pulmonary hypertension

Figure 3: Tyvaso sales for pulmonary hypertension in the US, 2016-25

LIST OF TABLES

Table 1: Tyvaso drug profile

Table 2: Tyvaso pivotal trial data in pulmonary hypertension

Table 3: Tyvaso ongoing late-phase trials in pulmonary hypertension

Table 4: Tyvaso sales for pulmonary hypertension in the US ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/t3e6b3

View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005710/en/

Pulmonary Hypertension Linked to Higher Right-Ventricular Stroke Work Index - The Cardiology Advisor

Posted: 12 Jul 2019 12:00 AM PDT

Individuals with pulmonary hypertension (PH) have higher right-ventricular stroke work index and right-ventricular minute work index and lower stroke volume divided by end-systolic volume (SV/ESV) due to left-sided heart disease, according to study results recently published in the Journal of Cardiothoracic and Vascular Anesthesia. Cardiac index was similar among the individuals studied.

This exploratory study included 33 individuals treated with cardiac surgery for left-sided heart disease, among whom 10 had PH (defined as pulmonary artery pressure ≥25 mmHg). All participants were aged 20 or older and underwent surgery from September 2016 and March 2018.

Right-ventricular stroke work index was evaluated by taking the integral of the pressure-volume curve. SV/ESV was used to estimate right ventriculo-arterial coupling. Individuals with and without PH due to left-sided heart disease were compared in terms of right ventricular energetics.

Due to a small sample size, the Mann-Whitney U test was used to examine the differences between groups, while the Fisher exact test was used to examine differences in binary variables.

Compared with no PH, individuals with PH had significantly higher right-ventricular stroke work index (690.7 mmHg·mL/m [95% CI, 601.6-737.1] vs 440.9 mmHg·mL/m [95% CI, 330.8-585.3]; P =.015) and right-ventricular minute work index (60,068 mmHg·mL/m²/min [95% CI, 35,547-68,741] vs 26,351 mmHg·mL/m²/min [95% CI, 17,316-32,517]; P =.011).

Cardiac index was statistically comparable between those with PH (2.5 L/min/m² [95% CI, 2.5-3.0]) and without (2.8 L/min/m² [95% CI, 2.4-3.0]; P =.798). Those with PH showed significantly lower SV/ESV compared with those without (0.520 [95% CI, 0.305-0.810] vs 0.820 [95% CI, 0.650-1.090]; P =.007).

At the end of surgery, those with PH were given a higher dose of catecholamine agents than those without (4.5 µg/kg/min [95% CI, 3.6-5.2] vs 2.8 µg/kg/min [95% CI, 2.5-3.2]; P =.003).

Limitations to this study include a small sample size and the use of simplified formulas to estimate end-systolic elastance, ventriculo-arterial coupling, and effective arterial elastance.

Study researchers concluded that "although cardiac index was similar between patients with and without PH because of [left-sided heart disease], [right-ventricular minute work index] was significantly higher in patients with PH. [Right-ventricular stroke work index] was significantly higher in patients with PH despite similar [stroke volume indexed for body surface area]. In addition, right ventriculo-arterial coupling (SV/ESV) was significantly lower in patients with PH, suggesting that patients with postcapillary PH have inefficient [right-ventricular] performance."

Reference

Kanemaru E, Yoshitani K, Kato S, Fujii T, Tsukinaga A, Ohnishi Y. Comparison of right ventricular function between patients with and without pulmonary hypertension owing to left-sided heart disease: assessment based on right ventricular pressure-volume curves [published online May 27, 2019]. J Cardiothorac Vasc Anesth. doi:10.1053/j.jvca.2019.05.025

Topics:

Pulmonary Hypertension Pulmonary Vasculature

Search This Blog

Pulmonary Hypertension